+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders



Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders



Journal of Urology 184(3): 1152-1157



Gross, intractable hematuria is rare in children. Although the role of epsilon aminocaproic acid in the management of refractory hematuria is well established in the adult population, few data exist about its use in children for this indication. We present our initial experience with epsilon aminocaproic acid for the treatment of intractable hematuria after more conservative measures failed, and propose an algorithm for administration of epsilon aminocaproic acid in children. We reviewed the charts of all patients treated with epsilon aminocaproic acid for intractable gross hematuria at our institution during a period of 36 months. All patients underwent hematological evaluation and any underlying bleeding dyscrasias were addressed. All patients also underwent renal and bladder ultrasound, retrograde pyelogram and ureteroscopy. Demographic information, medical and surgical histories, and epsilon aminocaproic acid dosing and outcomes were recorded. Three boys and 1 girl 11 to 17 years old were treated with epsilon aminocaproic acid. Three patients had sickle trait (1 with nutcracker phenomenon) and 1 had hemophilia A. Three patients required packed red blood cell transfusions to maintain hematocrit. Three renal angiograms were performed, all of which were nondiagnostic. Duration of hematuria ranged from 1 to 52 weeks before administration of epsilon aminocaproic acid. Endoscopic evaluation demonstrated hematuria localized to 1 ureteral orifice in all 4 patients. All patients received 100 mg/kg epsilon aminocaproic acid orally every 6 hours, which uniformly led to cessation of hematuria. Epsilon aminocaproic acid is useful for the management of gross refractory hematuria when more conservative measures fail. Because of its potential side effects, it should be used cautiously.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055122214

Download citation: RISBibTeXText

PMID: 20650477

DOI: 10.1016/j.juro.2010.05.020


Related references

Urinary incidents in the treatment of hematuria in hemophiliacs with epsilon-aminocaproic acid. Lille Medical 13(4): 408-412, 1968

Treatment with epsilon aminocaproic acid in persistent hematuria after renal punch biopsy. Semaine Therapeutique 40(4): 273, 1964

Treatment of hematuria in a hemophiliac by epsilon aminocaproic acid with concomitant urokinase determination. Bibliotheca Haematologica 26: 114-114, 1966

Renal complications during treatment of hematuria in hemophilia A with epsilon-aminocaproic acid (EACA). Polski Tygodnik Lekarski 26(4): 145-147, 1971

Arteriovenous fistula and prolonged hematuria after renal biopsy: treatment with epsilon aminocaproic acid. Canadian Medical Association Journal 110(6): 671, 1974

Treatment of hematuria in hemorrhagic diathesis by means of epsilon-aminocaproic acid with concomitant determination of urokinase. Folia Clinica Internacional 15(11): 537-538, 1965

Sudden relief of symptoms in a patient with mesangiocapillary glomerulonephritis during treatment of hematuria with epsilon aminocaproic acid. Polski Tygodnik Lekarski 46(40-42): 773-774, 1991

Sickle cell hematuria controlled by epsilon aminocaproic acid. Connecticut Medicine 39(12): 777-778, 1975

Epsilon-aminocaproic acid in traumatic renal hematuria in the rabbit. Investigative Urology 12(6): 458-460, 1975

Unilateral essential hematuria. Therapy with epsilon aminocaproic acid. Urology 23(3): 297-298, 1984

The use of epsilon aminocaproic acid in sickle cell trait hematuria. Journal of Urology 105(4): 552-553, 1971

Successful epsilon-aminocaproic acid therapy in a patient with unexplained hematuria. Clinical Pediatrics 16(2): 167-168, 1977

Preliminary Note on the Treatment of Eczema by Epsilon-Aminocaproic Acid. Bulletin de la Societe Francaise de Dermatologie et de Syphiligraphie 71: 224-227, 1964

Epsilon aminocaproic acid therapy of hematuria due to heterozygous sickle cell diseases. Journal of Urology 102(1): 93-95, 1969

Incidence of thrombosis associated with epsilon-aminocaproic acid administration and with combined epsilon-aminocaproic acid and subcutaneous heparin therapy. II. A clinical study with the aid of intravenous phlebography. Acta Chirurgica Scandinavica 136(3): 167-171, 1970